Author

L. Lupin-Jimenez

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 1 Research Focus:cell signaling & trafficking· 1 Research Focus:clustering· 1 Approach:deep learning· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1 Assay:flow cytometry· 1 Research Focus:host-pathogen & immune response· 1

Frequent Co-Authors

M. F. Krummel· 2 shared T. Courau· 2 shared A. A. Rao· 1 shared A. Edwards· 1 shared A. J. Combes· 1 shared A. J. Ritchie· 1 shared A. T. Mayer· 1 shared B. Samad· 1 shared

Activity by Year

2020-2023 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 30 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersImmunology

M. F. Krummel

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cyclone: an accessible pipeline to analyze, evaluate and optimize multiparametric cytometry data

R. K. Patel, R. G. Jaszczak, I. Kwok, N. D. Carey, T. Courau, D. Bunis, B. Samad, L. Avanesyan, N. W. Chew, S. Stenske, J. M. Jespersen, J. Publicover, A. Edwards, M. Naser, A. A. Rao, , G. K. Fragiadakis

Cyclone is a pipeline for analyzing, evaluating, and optimizing multiparametric cytometry data, demonstrating effectiveness across multiple cytometry technologies and biological contexts.

bioRxiv · Mar 8, 2023 · PreprintImmunology

Activating Immune Recognition in Pancreatic Ductal Adenocarcinoma Using Autophagy Inhibition, MEK blockade and CD40 Agonism

H. Jiang, T. Courau, L. Lupin-Jimenez, J. Borison, A. J. Ritchie, A. T. Mayer, M. F. Krummel, E. A. Collisson

This study shows that combining MEK inhibition, autophagy inhibition, and CD40 agonism activates the Type I Interferon/STING pathway in PDA tumors, reprograms TAMs, and enhances anti-tumor immunity in a mouse model.

bioRxiv · Nov 5, 2020 · PreprintCancer Biology